Growth hormone and bone mineral density in HIV-1-infected male subjects

European Journal of Medical Research

Volumn 13, Issue 4, 2008, Pages 173-178

  Teichmann, Joachim ^a,b   Lange, U ^b   Discher, T ^b   Lohmeyer, J ^b   Stracke, H ^b   Bretzel, R G ^b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Bone metabolism; GH; HIV; IGF I; IGFBP

Indexed keywords

AMPHOTERICIN B; CALCITRIOL; CALCIUM; COTRIMOXAZOLE; ETHAMBUTOL; GROWTH HORMONE; ISONIAZID; OSTEOCALCIN; RIFAMPICIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUMBAR SPINE; MALE; MYCOBACTERIOSIS; OSTEOPENIA; OSTEOPOROSIS; OUTPATIENT; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OSTEOCALCIN;

EID: 43849098189     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Grinspoon SK, Feingold KR. Metabolic disturbances and wasting in aquired immunodeficiency syndrome. New Engl J Medicine 1992; 327: 329-337.
2. Press M. Growth hormone and metabolism. Diabetes /Metabolism/ Reviews 1988; 4: 391-414.
3. Salomon F, Cuneo R, Sonksen PH. Growth hormone and protein metabolism. Hormone Research 332;36:41-43
4. Clemmons DR, Smith-Banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 1992; 75: 234-238.
5. Clemmons DR, Snyder DK, Williams R, Underwood LE. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J Clin Endocrinol Metab 1987; 64: 878-883.
6. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of GH and insulin-like growth-factor I In combination with insulin-like I by use of both agents simultaneously. J Clin Invest 1993; 93: 391-396
7. Clemmons DR, Cammmcho-Hubner C, Jones JI, McCusker RH, Busby WH. Insulin like growth factor binding proteins: mechanism of action at the cellular level. In Modern Concepts of Insulin-like-growth-factor (ed. EM Spencer) pp. 475-486, Elsevier New York 1993.
8. Baxter RC, Hizuka N, Takano K, Halman SR, Asakawa K: Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 complex to administration of insulin-like-growth factor I. Acta Endocrinol 1993; 128: 101-108.
9. Conover CA, Kiefer MC, Zapf J. Posttranslational regulation of insulin-like growth-factor binding protein 4 in normal and transformed human fibroblasts. Insulin-like growth factor dependence and biological studies. J Clin Invest 1993; 91: 1129-1137.
10. Dahn MS, Lange MP, Jacobs LA. Insulin like growth factor binding-production is inhibited in human sepsis. Arch Surg 1988; 123: 1409-1414.
11. Frost RA, Berekett A, Woijnar MM, Wilson TA, Lang CH, Gelato MC. Phosphorylation of human-insulin like growth factor binding protein-1 in patients with insulin-dependent diabetes mellitus and severe trauma. J Clin Endocrin Metab 1994; 78: 1533-1535.
12. Ross R, Miell J, Freeman E. et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth-factor-I. Clin Endocrinol 1991; 35: 47-54.
13. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelanm M. Metabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77: 956-962.
14. Liebermann SA, Butterfield GE, Harison D, Hofman AR. Anabolic effects of recombinant insulin-like growth-factor I in cachectic patients with aquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994; 78: 404-410.
15. Zaloga GP, and Chernow B. The multifactorial basis for hypocalcemia during sepsis studies of parathyroid hotmone-vitamine D axis. Ann Int Med 1987; 107: 36-41.
16. Kuehn EW, Anders HJ, Bogner JR, Obermaier J, Goebel FD, Schlöndorff D. Hypocalcaemia in HIV-infection and AIDS. J Intern Med 2001; 245: 69-73.
17. Dluhy RG. The growing spectrum of HIV-releated endocrine abnormalities J Clin Endocrinol Metab 1990; 70: 563-565.
18. Glass AR, and Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxy-vitamin D, total serum calcium in hypercalcemic patients. J Clin Endocrinol Metab 1988; 66: 934-938.
19. Jacobs MB. The aquired immune deficiency syndrome and hypercalcemia. West J Med 1986; 114: 467-471.
20. Pont A. Unusual causes of hypercalcemia. Endocrinol Metabol Clin North Am 1989; 18: 753-764.
21. Hernandez Quero J, Centeno NO, Munoz-Torres M, Martinez-Perez A, and Higuera Torres-Puchol J M. Alterations in bone turnover in HIV-positive patients. Infection 1993; 21: 220-222.
22. Serrano M, Marinoso JC, Soriano JC, Rubies-Prat J, Aubia J. Coll, J, Bosch J, Del Rio I, Vila J, Goday A, and Nacher M. Bone remodeling in human immunodeficiency virus-1-1infected patients. A histomorphometric Study. Bone 1995; 16: 185-191.
23. Teichmann J, Stephan E, Discher T, Lange U, Federlin K, Stracke H, Friese G, Lohmeyer J, Bretzel RG: Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection. Metabolism 2000, 49: 1134-1139.
24. Tebas P, Powderly WG, Claxton S, Marin D, Tantisriwat T, Teitelbaum SL, Yarasheski KE: Accelerated bone and mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14: 63-67.
25. Bühl A, and Zöfel P. SPSS für Windows Version 6. Addison-Wesley; 1994.
26. Carr A, Miller J, Eisman JA, Cooper DA: Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001,15: 703-709.
27. Frost RA, Fuhrett J, Steigbigel R, Mariuz P, Lang ChH, Gelato MC: Wasting in the aquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol 1996; 44: 501-514.
28. Salbe AD, Kotler DP, Wang J, Pierson RN, Campbell RG: Correlation between serum insulin like growth factor I concentrations and nutritional status in HIV-infected individuals. Nutr Res 1995; 15: 1437-1443
29. Benbassat CA, Lazarus DD, Cichy SB, Evans TM, Moldawer LL, Lowry SF, Unterman SF: Interleukin 1a and Tumor necrosis factor a regulate insulin-like growth factor binding protein-1 levels and mRNA abundance in vivo and in vitro.Horm Metab Res 1999; 31: 209-215
30. Spanos E, Barrett D, MacIntyre I, Pike JW, Safilian EF, Haussler MR: Effect of growth hormone on vitamin D metabolism. Nature 1978; 273: 246-247.
31. Gray RW, Garthwaite TL: Activation of renal 1,25-dihydroxyvitamin D3 synthesis by phosphate deprivation: evidence for a role for growth hormone. Endocrinology 1985; 116: 189-193.